Skip to content

Source filing unavailable

Q1 2020 · —
Revenue—
Net Income-$6.40MN/M vs Q1 2019N/M vs Q4 2019
EPS Diluted-$0.90no prior Q1 2019 on fileno prior Q4 2019 on file
Operating Income-$5,831,000N/M
Operating Cash Flow-$7,761,000N/M
Free Cash Flowderived-$7,773,000—

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ1 2020Q1 2019
Net Income-$6.40M-$10.77M
EPS Diluted-$0.90—

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Compass Therapeutics, Inc. · CIK 1738021 · Engraved from SEC EDGAR